Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Affimed NV (EM) AFMDQ

Healthcare Biotechnology
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24... see more

Current News (EXPM:AFMDQ)

Affimed Announces Receipt of Nasdaq Delisting Notice

GlobeNewswire May 14, 2025

Affimed Announces Filing for the Opening of Insolvency Proceedings

GlobeNewswire May 13, 2025

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

GlobeNewswire April 29, 2025

Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

GlobeNewswire April 23, 2025

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

GlobeNewswire April 21, 2025

Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting

GlobeNewswire March 25, 2025

Affimed to Present at the Leerink Partners Global Healthcare Conference 2025

GlobeNewswire March 3, 2025

Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)

GlobeNewswire December 17, 2024

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

GlobeNewswire December 9, 2024
View More News ››

Opinion & Analysis (EXPM:AFMDQ)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:AFMDQ)

Using technical analysis for this one.

Buy Order was filled today at $2.43 cents per share,so good luck to all of us shareholders out there.
coolfooldumbguy - December 5, 2024

BUY BUY BUY BUY BUY

Big time news
Nibinator - June 12, 2024

BUY BUY BUY BUY BUY

Big time news
Nibinator - June 12, 2024
View more Bullboard ››

Sorrento Resources Ltd.

Sorrento Resources Ltd.

Sorrento is engaged in acquisition, exploration, and development of mineral property assets in Canada. Sorrento’s objective ...
View More »

Podcasts